Nicolas Maignan
Chief Operating Officer at Kantify, Belgium
“Unlocking and Accelerating Drug Discovery with Artificial Intelligence: The Kantify Approach“
Abstract
In this session, we will explore how Kantify leverages artificial intelligence to innovate and expedite the drug discovery process. Focusing on small molecule therapeutics, I will introduce Kantify’s AI-driven Sapian suite, designed to predict interactions between small molecules and proteins, evaluate ADMETox properties, and identify target proteins that mediate molecule effects. Our models, including Sapian.Hit for hit prediction, Sapian.Ward for ADMETox evaluation, and Sapian.Target for target discovery, enable robust insights across therapeutic areas. Through real-world case studies, I will showcase applications such as the identification of novel ion channel modulators, target deconvolution for oncology and neuromuscular disorders, drug repositioning, and a unique example involving plant research. Join us to see how AI is transforming the landscape of drug discovery and therapeutic innovation.
https://www.kantify.com/insights/Viagra_Sildenafil_AI_therapeutic_targets_Behind_The_Pill
Short Bio
Nicolas Maignan is the Chief Operating Officer at Kantify, a Belgian company pioneering AI-driven drug discovery. With 8 years of experience in machine learning, Nicolas has led innovative projects across diverse applications, from heart failure detection through signal processing to large-scale train delay and occupancy prediction. He led a machine learning team of skilled engineers and spent four years as a general ML consultant before focusing on drug discovery. Nicolas is a graduate engineer from the French National Polytechnic Institute and now applies his expertise to advance Kantify’s mission of accelerating therapeutic discovery through artificial intelligence.
Kantify is a Belgian company specializing in computational drug discovery using artificial intelligence. Their proprietary AI platform, Sapian, accelerates the identification and design of small molecule therapeutics and targeted protein degraders across various diseases, including oncology, neurology, and neuromuscular disorders. By leveraging AI, Kantify aims to address the significant gap in available therapies, with 95% of diseases lacking approved treatments, and to revolutionize human health by developing safe and effective drugs more efficiently.
If anyone is interested in meeting with the speaker, please contact Jorge Lozano (lojujo@ibmcp.upv.es).
